Giorgio Kradjian

The immunocytokine NHS-IL12 as a potential cancer therapeutic

Jonathan K. Fallon, Robert M. Tighe, Giorgio Kradjian et al. · Oncotarget · 2014 · 154 citations · Full text

Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models

Chunxiao Xu, Yanping Zhang, Alex Rolfe et al. · Clinical Cancer Research · 2017 · 74 citations

Dual A2A/A2B Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i>

Kai Schiemann, Natalya Belousova, Armine Matevossian et al. · Molecular Cancer Therapeutics · 2024 · 12 citations